91Ӱ

Award

'Simple things can go wrong … and cause disease'

Christi Thomas
By Christi Thomas
July 2, 2024

In her first year as a graduate student at the University of Helsinki, Jenny Hogstrom attended a conference in Boston organized by the American Association for Cancer Research. She already liked the basic science behind cancer research and the fact that it could make a difference for many people. The meeting increased her interest.

Jenny Hogstrom
Courtesy of Jenny Hogstrom
Cancer biologist Jenny Hogstrom received a JBC Tabor award for her use of organoids to study drug resistance in cancer. 

“Cancer biology is interesting because simple things can go wrong in your body and cause disease,” she said. “I heard amazing talks and attended mentoring sessions organized by women in cancer research, and it was inspiring hearing postdocs and their journeys.” 

Hogstrom earned her Ph.D. in medicine and oncology. Her graduate research focused on gene regulation in intestinal stem cells and colorectal cancer.

She then looked back to the Boston area to continue her research. But after spending most of her life in Finland, moving to the U.S. for a postdoctoral fellowship at Harvard Medical School was difficult. 

“Learning how things work here was the biggest headache,” she said. “The bureaucracy was hard to get used to.”

However, she advises trainees who are hesitant about making such a move to go for it. “If there is some lab and science and it is in another country or place, be brave and move — you meet new people and grow as a person.”

Hogstrom is now working toward completing her postdoctoral studies. Her first project involves how changes in the metabolism of breast cancer cells affect drug resistance to targeted therapies. She is also studying how cancer-associated fibroblasts stimulate resistance to CDK4 inhibitors in breast cancer cells.

Hogstrom faced a stumbling block when she tried to grow patient-derived organoids that maintained estrogen receptor–positive expression. She used biopsied bone tissue, which is rarely studied and even less often used for research models. She sought help from experts, she said, and juggled her projects to keep them all moving forward, trying to focus on each while keeping in mind the bigger picture.

“Some days when nothing is working, it is hard,” she said, “Whether it is positive data or negative data, at least it is data, and it tells you something, and this motivates me.” 

Hogstrom’s persistence was rewarded with a 2024 JBC/Herbert Tabor Early Career Investigator Award for about this work.

She hopes to study drug resistance in other cancers and develop more patient-derived organoid cultures from different tissues. 

Outside the lab, Hogstrom likes to travel and spend time with her dog Paddy.

Using organoids to study drug resistance in HR+ breast cancer

In recurrent hormone receptor–positive, or HR+, breast cancer, tumor cells have either estrogen or progesterone receptors or both, and the downstream signaling promotes tumor growth. Few good models, either animals or cell lines, exist for studying this cancer.

Jenny Hogstrom and her lab found a clinically relevant way to study HR+ breast cancer by culturing HR+ breast cancer patient-derived organoids, or HR+ PDOs, and matching cancer-associated fibroblasts, or CAFs, from primary and metastatic breast cancer. 

Hogstrom and her colleagues cultured HR+ PDOs that maintained estrogen receptor expression long enough to determine if they responded to therapy. Also, they compared the original patient’s drug responses and PDOs’ responses to targeted therapies such as ER targeting and CDK4/6 inhibitors. Sometimes, the team saw drug sensitivity in PDOs but resistance in the patients’ drug responses. This could be due to the tumor’s extrinsic factors, such as the stromal environment, influencing responses.

CAFs in breast cancer have many subtypes; some promote tumor cell proliferation and drug resistance, while the function of others is unknown. The researchers found an increase in the expression of cytokine-responsive pathways in PDOs with CAF-conditioned media and saw many cytokines causing resistance to the chemotherapy drug fulvestrant.

The research Jenny Hogstrom and her colleagues published in JBC allows researchers to use high take-rate HR+ PDOs to test for drug resistance. Patients do not need to participate in multiple clinical trials to identify drug targets to advance basic and translational research.

Enjoy reading 91ӰToday?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Christi Thomas
Christi Thomas

Christi Thomas holds a B.S. in biochemistry with a minor in biology from California State University Northridge. She is a volunteer writer for 91ӰToday.
 

Get the latest from 91ӰToday

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in People

People highlights or most popular articles

Fliesler wins scientific and ethical awards
Member News

Fliesler wins scientific and ethical awards

July 21, 2025

He is being honored by the University at Buffalo and the American Oil Chemists' Society for his scientific achievements and ethical integrity.

Hope for a cure hangs on research
Essay

Hope for a cure hangs on research

July 17, 2025

Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson’s fight for survival and hope. Without funding, science can’t “catch up” to help the patients who need it most.

Before we’ve lost what we can’t rebuild: Hope for prion disease
Feature

Before we’ve lost what we can’t rebuild: Hope for prion disease

July 15, 2025

Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal — and just getting started.

91Ӱmembers recognized as Allen investigators
Member News

91Ӱmembers recognized as Allen investigators

July 14, 2025

Ileana Cristea, Sarah Cohen, Itay Budin and Christopher Obara are among 14 researchers selected as Allen Distinguished Investigators by the Paul G. Allen Family Foundation.

AI can be an asset, 91Ӱeducators say
Advice

AI can be an asset, 91Ӱeducators say

July 9, 2025

Pedagogy experts share how they use artificial intelligence to save time, increase accessibility and prepare students for a changing world.

91Ӱundergraduate education programs foster tomorrow’s scientific minds
Feature

91Ӱundergraduate education programs foster tomorrow’s scientific minds

July 8, 2025

Learn how the society empowers educators and the next generation of scientists through community as well as accreditation and professional development programs that support evidence-based teaching and inclusive pedagogy.